05.12.26 -- C> CDMOs: On The Path To $75 Billion In Services?

Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.

Assimilate how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

Small, early operational decisions accumulate over time, creating hidden variability that emerges at scale, making standardization essential for stability, reproducibility, and regulatory confidence.

New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.

Plasmid engineering and process development boosted viral titer 12.5×, eliminating manufacturing bottlenecks and enabling an on‑time regulatory submission for the cell therapy program.

By integrating perfusion into upstream manufacturing, see how this approach has achieved up to a fivefold increase in productivity, delivering titers that significantly exceed current industry benchmarks.

Discover how AI-enabled digital validation shifts manufacturers from reactive compliance to predictive intelligence, connecting validation, asset, and quality data to accelerate digital maturity.

A new platform approach streamlines lentiviral vector design and manufacturing, boosting yield, lowering costs, and accelerating access to gene‑modified cell therapies worldwide.

Viral vectors are the indispensable backbone of genetic medicine. Uncover the fundamental trade-offs and manufacturing strategies for large-scale production of AAV and lentiviral delivery systems.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

Review how one family's race against time led to the creation of a groundbreaking gene therapy for their daughter, just 14 months after her ultra-rare disease diagnosis.

Browse how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.